Cooperative Agreement 2527074
Award Date 9/1/25
Completion Date 8/31/27
Dollars Obligated $1.2M
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Cooperative Agreement
Place of Performance
Newton, MA 02459, USA
Similar Awards
- This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $274,987 to Xheme Inc. will develop a completely non-toxic blood bag to replace the current polyvinyl chloride (PVC) bags that use toxic plasticizers. The new technology aims to extend the shelf life of whole blood by protecting against cold storage-induced damage, addressing the urgent need created by the European Union's ban on the toxic plasticizer in PVC blood bags and the...
- The National Science Foundation awarded Xheme Inc. a $255,871 Project Grant under the Engineering federal grant program (CFDA 47.041) from July 1, 2021 to June 30, 2022. The grant funds structure property relationship studies to design next-generation nanocomposite blood bags. As part of its mission to improve engineering innovation and education, the NSF Directorate for Engineering seeks to enable new materials and product design through foundational research like the structure-property...
- Hermes Life Sciences LTD received a $1,126,590 cooperative agreement award from the National Science Foundation under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084) to support the SBIR PHASE II: BLOOD-PLASMA SEPARATION FOR POINT-OF-CARE DIAGNOSTIC TESTING project. The funding period is from August 1, 2021 through January 31, 2024. Under this cooperative agreement, Hermes Life Sciences LTD will develop technologies for blood-plasma separation to enable point-of-care...
- The National Science Foundation (NSF) awarded a $304,906 Small Business Innovation Research (SBIR) Phase I Project Grant to Seabird Lifesciences LLC under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program. The project aims to develop an innovative bioprinting approach for creating vascular grafts that closely mimic the properties of natural blood vessels. The approach utilizes a specialized bioprinting process that integrates a double-network hydrogel made from a Dacron...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $295,963 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to New Health Sciences, Inc. (Hemanext Inc.) to evaluate the hemostatic function of platelets stored under hypoxic conditions for whole blood (WB) transfusion. The project aims to develop an improved WB storage platform that maintains an oxygen-managed environment to provide higher quality red blood cells for oxygen delivery and shock reversal, while...
- This Project Grant award from the National Heart, Lung, and Blood Institute's Cardiovascular Diseases Research program (CFDA 93.837) totaling $715,110.00 aims to develop and optimize a novel "nano-RBC" blood substitute prototype. The key products and services to be delivered include: The project will use computational studies, synthetic and biological experiments to design a "smart" oxygen-delivery biomaterial with physiological oxygen binding/dissociation properties,...
- This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award supports the development of a novel device that can rapidly and automatically extract pathogen DNA from whole blood samples to enable faster diagnosis of sepsis. The $274,858 award to New England Hemolytics, Inc., with a project period from September 1, 2024 to February 28, 2025, will fund the testing and optimization of this technology across common sepsis-causing pathogens. The...
- This $568,264 Project Grant (R41HL178144) was awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) to SAFI Biotherapeutics Inc., a pre-clinical blood cell therapy company based in Cambridge, MA. The goal of this Phase I STTR project is to develop a scalable bioprocess for manufacturing designer red blood cells (RBCs) derived from induced pluripotent stem cells (iPSCs). These designer RBCs will serve as reagents to...
- The National Science Foundation awarded a $255,911 Project Grant to Frontier Bio Corporation of Oakland, California under the Engineering federal grant program (CFDA 47.041). The grant will support the development of novel advanced manufacturing techniques for artificial blood vessels from August 15, 2021 through May 31, 2022. The Engineering program seeks to improve quality of life and economic strength by fostering innovation and excellence in engineering research. This award will further...
- The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), awarded a $1,017,232 Project Grant to New Health Sciences, Inc. (doing business as Hemanext Inc.) to rigorously assess the efficacy of hypoxic red blood cell (HRBC) transfusions compared to conventional red blood cell (CRBC) transfusions in patients with sickle cell anemia. This 3-year project aims to evaluate the potential of HRBC transfusions as an alternative treatment...